CRISPR Therapeutics (NASDAQ:CRSP) Given New $120.00 Price Target at Truist Financial
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target hoisted by equities researchers at Truist Financial from $100.00 to $120.00 in a report issued on Wednesday,Benzinga reports.
Tower Semiconductor (NASDAQ:TSEM) Earns Buy Rating from Benchmark
Benchmark reaffirmed their buy rating on shares of Tower Semiconductor (NASDAQ:TSEM – Free Report) in a report published on Tuesday morning,Benzinga reports. The brokerage currently has a $60.00 ...
Hosted on MSN17h
Lowe’s Stock Outlook: Is Wall Street Bullish or Bearish?
Lowe's Companies, Inc. (LOW) is a leading home improvement retailer serving homeowners, professionals, and contractors across North America. Headquartered in Mooresville, North Carolina, Lowe’s ...
LP Building Solutions hikes dividend to $0.28 per share
NASHVILLE - LP Building Solutions (NYSE: LPX) announced today that its Board of Directors has approved an 8% increase in the ...
Truist Financial Sticks to Their Buy Rating for Republic Services (RSG)
In a report released today, Tobey Sommer from Truist Financial reiterated a Buy rating on Republic Services (RSG – Research Report), with a ...
Truist Financial Keeps Their Buy Rating on DraftKings (DKNG)
In a report released today, Barry Jonas from Truist Financial maintained a Buy rating on DraftKings (DKNG – Research Report). The company’s ...